Autolus Therapeutics Unveils Expanded Next Generation Technology and Pipeline and Provides Key Update on AUTO3 Program in Pediatric ALL at R&D Day LONDON, March 26, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next generation programmed T cell therapies for the...

Autolus Therapeutics to Host R&D Day on March 26, 2019 Company to highlight next-generation, novel programmed T cell therapies in development for hematological and solid tumor indications Program and webcast to begin at 8:00 am ET LONDON, March 07,...